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Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system, with a complex etiology
that includes a strong genetic component. The contribution of the major histocompatibility complex (MHC) has
been established in numerous genetic linkage and association studies. In addition to the MHC, the chromosome
19q13 region surrounding the apolipoprotein E (APOE) gene has shown consistent evidence of involvement in MS
when family-based analyses were conducted. Furthermore, several clinical reports have suggested that the APOE-
4 allele may be associated with more-severe disease and faster progression of disability. To thoroughly examine
the role of APOE in MS, we genotyped its functional alleles, as well as seven single-nucleotide polymorphisms
(SNPs) located primarily within 13 kb of APOE, in a data set of 398 families. Using family-based association
analysis, we found statistically significant evidence that an SNP haplotype near APOE is associated with MS
susceptibility ( ). An analysis of disease progression in 614 patients with MS from 379 families indicatedPp .005
that APOE-4 carriers are more likely to be affected with severe disease ( ), whereas a higher proportion ofPp .03
APOE-2 carriers exhibit a mild disease course ( ).Pp .02
Introduction
Multiple sclerosis (MS [MIM 126200]) is a chronic in-
flammatory disorder of the CNS characterized by de-
struction of the myelin sheath, gliosis, varying degrees
of axonal pathology, and progressive neurological dys-
function (Hauser and Goodkin 2001). MS is a major
cause of morbidity and disability in young adults, with
a prevalence of 0.1% in individuals of northern Euro-
pean origin (Kurtzke 1983; Rosati 1994). Genetic fac-
tors have been implicated by numerous studies, with an
estimated sibling-recurrence risk of 20%–40% and a
greatly increased concordance rate in MZ, compared
with DZ, twins (Sadovnick et al. 1993; Ebers et al.
1995). Earlier clinical studies and recent genomic screens
(Ebers et al. 1996; Sawcer et al. 1996; Haines et al. 1996;
Kuokkanen et al. 1997) have found the strongest and
most widely replicated evidence for an MS susceptibility
gene at the major histocompatibility complex (MHC)
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region on chromosome 6p21.3. Here, the class II DR2
haplotype of the human leukocyte antigen (HLA) sys-
tem (HLA-DRB1*1501-DQA1*0102-DQB1*0602)
has been consistently associated with predisposition to
MS in white populations of northern European descent.
HLA has been estimated to account for 17%–62% of
the genetic component of MS susceptibility (Haines et
al. 1998), but the exact mechanism by which it increases
disease risk has not yet been determined.
One of the first non-MHC regions of interest iden-
tified through linkage analysis was chromosome 19q13,
near the apolipoprotein E (APOE [MIM 107741]) locus
(Haines et al. 1993, 1996). Three other genomic screens
(Ebers et al. 1996; Sawcer et al. 1996; Kuokkanen et
al. 1997) have shown some support for linkage to this
region, and a meta-analysis of all four genomic screens
(Wise et al. 1999) identified 19q13 as the second-most-
significant region after the MHC. Additional evidence
for this region came from allelic association studies
(Barcellos et al. 1997; Zouali et al. 1999; D’Alfonso et
al. 2000) and, more recently, from follow-up analyses
by the Multiple Sclerosis Genetics Group (MSGG) in
both North American (Pericak-Vance et al. 2001) and
San Marinese populations (Haines et al. 2000). As with
most complex diseases, the data are not entirely con-
sistent; not all studies have shown evidence of linkage
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(Chataway et al. 1998; D’Alfonso et al. 1999), and as-
sociation results were based on polymorphisms in dif-
ferent markers.
One of several candidate genes in the 19q13 region
is the APOE gene, which codes for a major lipid carrier
protein (apoE) in the brain. The apoE protein has long
been associated with regeneration of axons and myelin
after lesions of central and peripheral nervous tissue
(Ignatius et al. 1986), and its isoforms have been shown
to have differential effects on neuronal growth (Nathan
et al. 1994). Because decreased apoE concentrations
have been observed in cerebrospinal fluid in patients
with MS, some investigators have proposed that a cor-
responding decrease in intrathecal apoE synthesis influ-
ences the degree of MS exacerbation (Rifai et al. 1987;
Gaillard et al. 1998). Immunomodulatory and antiox-
idant effects of APOE have also been reported (Las-
kowitz et al. 1998). Therefore, both coding-region poly-
morphisms and promoter-region variants that modify
APOE expression levels are plausible MS candidate
genes. In clinical and epidemiologic studies, the role of
APOE in MS has been somewhat controversial because
of reports of both the presence (Dousset et al. 1998;
Evangelou et al. 1999; Lucotte et al. 2000) and the
absence (Ferri et al. 1999; Pirttila¨ et al. 2000;Weatherby
et al. 2000a, 2000b) of an association of the APOE-4
allele with susceptibility to or severity of the disease.
The limited sample sizes of many of these earlier studies
may partly explain the inconsistent findings. Recently,
two larger studies reported statistically significant evi-
dence of a more severe clinical course among APOE-4
carriers with MS. One of these studies (Fazekas et al.
2001) employed a disease activity score (progression
index [Weinshenker et al. 1997]) to measure MS se-
verity, whereas the other study (Chapman et al. 2001)
examined latency to severe disease, by use of a Cox-
regression model.
Given the strong evidence of a potential role of APOE
in MS, the goal of the present study was to test the
functional APOE polymorphism (alleles e2, e3, and e4)
and several nearby single-nucleotide polymorphisms
(SNPs) for association with MS susceptibility or sever-
ity. The SNPs used were a subset of those previously
found to be in linkage disequilibrium (LD) with the
APOE polymorphism and to be associated with late-
onset Alzheimer disease (Martin et al. 2000a), in which
the APOE-4 allele is known to increase disease suscep-
tibility (Corder et al. 1993; Saunders et al. 1993). To
extract as much transmission information as possible,
statistical methods included both single- and multilocus
family-based association analyses. Genotype-phenotype
association analyses, based on clinical variables among
patients with MS, were also performed.
Subjects and Methods
Subjects
A total of 398 white families that included one or
more affected members were ascertained by the Univer-
sity of California at San Francisco and a network of
collaborating clinical sites throughout the United States.
Ascertainment methods included physician referrals,
self-referrals, and responses to advertisements, as de-
scribed elsewhere (Haines et al. 1996). Family ascer-
tainment focused on probands with relapsing-remitting
MS, thus enriching our overall patient sample for this
disease type, relative to primary progressive MS. Of the
398 families, 148 had two or more sampled affected
relatives. This includes most of the original 52 multiplex
families genotyped in our genome screen (Haines et al.
1996) and the 46 families ascertained for follow-up anal-
ysis (Haines et al. 1998). An effort was made to extend
the multiplex families through all affected first-degree
relatives. The 250 additional families had one sampled
affected member and no record of affected relatives. To
include these families in our association analysis, one or
more unaffected siblings and/or both parents of the pa-
tient were sampled as well. The collection of subjects
and all experiments were performed under the approval
of the committee of human research of the University
of California at San Francisco. Institutional review
board approval at all study sites and informed consent
from all study participants were obtained. All affected
family members were examined or had their medical
records reviewed by one of the authors (S.L.H.), ac-
cording to criteria described elsewhere (Goodkin et al.
1991). Only individuals with definite MS were consid-
ered as affected in the analyses.
The 398 families included a total of 633 patients with
MS. For 614 of them (from 379 families), additional
clinical variables were available for analysis of disease
progression. A detailed definition of clinical features for
these patients has been reported elsewhere (Barcellos et
al. 2001). In brief, age at onset was defined as the first
episode of neurological dysfunction suggestive of de-
myelinating disease. This information was obtained via
patient recall and verified through review of medical
records. Disability was assessed at entry by use of the
Expanded Disability Status Scale (EDSS) (Kurtzke 1983)
and was recorded in five categories (!3, 3 to !6, 6, 6.5,
and 7). EDSS scores were used in conjunction with
disease duration to define mild (ability to walk normally
or only mild gait disability) and severe (need for bilateral
assistance to walk or wheelchair dependency) forms of
MS (Barcellos et al. 2001). Finally, the number of years
from disease onset until a patient reached an EDSS score
7 (wheelchair dependency) was recorded whenever
possible. The 614 patients included in the analysis of
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Table 1
Marker Characterization for Panel of SNPs Genotyped in 398
Families of Patients with MS
SNP
Distance
from APOE
(kb) Change Minor Allelea Frequencyb
469 900 ArC A (1) .13
457 40 GrT T (2) .44
992 1.0 TrC T (1) .38
APOE 0 … … .12c
952 5′ UTR CrG G (2) .37
873 2.5 GrC C (2) .41
888 4.6 TrC T (1) .46
988 12.0 ArG G (2) .20
a Numeric labels (in parentheses) match those used in the text.
b Estimated from genotyped founders with unknown or unaf-
fected MS phenotype (individuals at the top of the pedigree and
unrelated spouses, chromosomes).np 602–656
c Frequency for APOE e4.
Figure 1 Physical map of SNPs on cosmid F19374 containing APOE. snp888 and snp988 are within the TOM40 gene (LocusLink 10452).
snp952 is in the 5′ UTR of APOE. A functional relationship with any particular APOE allele or other effect on APOE expression is not known.
disease progression consisted of 379 probands, 178 sib-
lings, 6 parents, 10 offspring, 18 avuncular relatives, 16
cousins, and 7 more distant relatives of the probands.
DNA Analysis and Genotyping
Genomic DNA was extracted from whole blood after
isolation of blood lymphocytes according to established
protocols (Vance 1998). APOE and HLA genotyping
were performed as described elsewhere (Saunders et al.
1993; Barcellos et al. 2001). The generation and map-
ping of the SNPs used in the present study have been
reported elsewhere (Lai et al. 1998;Martin et al. 2000a).
SNP genotyping was performed by an oligonucleotide
ligation assay (Eggerding et al. 1995), as described else-
where (Martin et al. 2001b). A map of the SNPs, most
of which are located in GenBank cosmid F19374 (ac-
cession number AF050154), is shown in figure 1. Allele
designations and frequencies of all SNPs are given, for
reference, in table 1. Note that allele frequencies were
estimated from genotyped founders (individuals at the
top of the pedigree and unrelated spouses) with un-
known or unaffected phenotypes but were not relevant
to the association analyses described below.
In accordance with quality-control (QC) procedures
described elsewhere for fine-mapping (Rimmler et al.
1998), samples for six individuals were duplicated for
each 96-well plate, and samples from the Centre d’Etude
du Polymorphisme Humain were also included on all
plates, with the laboratory technicians blinded to their
location. Genotypes for the QC samples within and
across plates were compared, to detect potential loading
and reading errors and thus to minimize the actual ge-
notype error rate. After the genotypes had passed the
QC checks, they were uploaded into the PEDIGENE
database and merged into the Lapis management system
for creating analysis-input files (Haynes et al. 1995).
Statistical Analysis
Family genotypes were examined for Mendelian in-
consistencies, using PedCheck (O’Connell and Weeks
1998). Samples yielding inconsistent results were sent
back to the laboratory technician, without family-iden-
tifying information, for rereading. Given the small dis-
tances between markers (see fig. 1), families with obli-
gate recombinants, as determined by haplotype analysis
with SIMWALK2 (Sobel and Lange 1996), were reread
and, if necessary, regenotyped.
Tests for Hardy-Weinberg equilibrium (HWE) at
each marker and for LD between pairs of markers
were conducted separately in a sample of unrelated af-
fected individuals (one from each family) and a sample
of unrelated unaffected individuals (one from each fam-
ily, if available). Although individuals are independent
within samples, there is clearly dependence between the
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two samples; however, we were interested only in esti-
mating the extent of HWE and LD between markers,
without formally testing whether it is different in af-
fected versus unaffected individuals. An exact test of
pairwise LD implemented in the Genetic Data Analysis
program (Zaykin et al. 1995) was used.
Family-Based Association Analysis
To test the markers for linkage and association with
MS, the data were analyzed with the Pedigree Disequi-
librium Test (PDT) (Martin et al. 2000b, 2001) and with
the likelihood-ratio test implemented in TRANSMIT
(Clayton 1999). PDT can analyze only one marker locus
at a time, whereas TRANSMIT is able to consider the
transmission of multiple marker haplotypes, even in the
presence of phase uncertainty andmissing parental geno-
types. For this haplotype analysis, TRANSMIT assumes
absence of recombination between markers; thus, this
analysis was applied only to the interval between snp992
and snp988, where markers were spaced 1–7 kb apart
and where no recombinations were expected to occur in
our sample, given the observed number of meioses
(∼2,080). Genotypes for families that did show evidence
of recombinations in this interval were regenerated, and
the discrepancy could be resolved for all families in-
cluded in this analysis.
TRANSMIT two- and three-locus analyses were per-
formed, using a sliding-window approach, to examine
haplotypes for each successive set of adjacent SNPs.
Four- and five-locus analyses were performed only for
selected haplotypes, in which two- and three-locus anal-
yses indicated a possible association with disease sus-
ceptibility. A formal correction for multiple testing was
considered too conservative, especially because of the
high level of pairwise LD between the SNPs.
Analysis of APOE and Disease Progression
Analyses that examined the relationship of APOE-4
and APOE-2 carrier status and clinical variables were
also conducted. Methods that take into account the cor-
relation of multiple affected members from the same
families were used throughout. Specifically, a logistic-
regression model with variance estimation based on gen-
eralized estimating equations (PROC GENMOD, SAS
version 8.0; SAS Institute) was used to model a binary
variable that quantifies disease severity (defined in the
“Results” section) as a function of several covariates of
interest. To model disease severity as an ordinal response
variable, a proportional-odds model (Agresti 1990) was
employed. Here, the association was measured by an
odds ratio for being in a disease severity category j
(jp1 for mild, jp2 for moderate, jp3 for severe MS,
see the “Results” section) rather than 1j for exposed
versus unexposed patients, under the assumption that
this odds ratio is independent of the particular categories
used. Familial correlations in the multiplex data were
accounted for by use of generalized estimating equa-
tions, using a publicly available SAS macro (Williamson
et al. 1999). Finally, we analyzed a Cox-regressionmodel
based on latency to EDSS score 7 as a censored re-
sponse variable. This was similar to the analysis by
Chapman et al. (2001), except that their study defined
the event as EDSS 4 and 6, respectively. Familial
correlations were accounted for by using the robust var-
iance estimate of the Cox-regression parameters (Lin and
Wei 1989), as implemented in the STATA package (ver-
sion 7.0; StataCorp 2001).
Results
No evidence of deviations from HWE for any of the
eight markers was found in the samples of affected
( ) or unaffected ( ) individuals (np 398 np 214 P 
). In both affected and unaffected subjects, there was.09
strong LD ( ) between each pair of the snp992,P ! .0001
APOE, snp952, snp873, snp888, and snp988 markers.
Family-Based Association Analysis
The results of the PDT and TRANSMIT single-locus
analysis, as well as TRANSMIT multilocus analyses, are
shown in table 2. The single-locus analyses did not show
any evidence of association, but significant results were
observed for several multilocus haplotypes within this
region. Both the global and haplotype-specificmultilocus
results indicated that the 21112 haplotype of markers
APOE, snp952, snp873, snp888, and snp988 was as-
sociated with increased MS susceptibility ( forPp .02
five-marker haplotype, and for four-markerPp .005
haplotype without snp988; both are uncorrected P val-
ues from the TRANSMIT global test). The first “2” allele
in this haplotype is the APOE-2 polymorphism. The
other (lower-order) significant multilocus tests shown in
table 2 result from analyzing subsets of these five alleles
and illustrate that the haplotype effect is seen consis-
tently, regardless of the number of loci jointly analyzed.
When families were stratified by HLA-DR2 status (216
families with presence and 149 families with absence of
DR2 in all affected individuals), similar single-locus and
multilocus haplotype associations were observed in both
subgroups (data not shown).
Analysis of APOE and Disease Progression
A summary of clinical variables among the patients
with MS is shown in table 3. To analyze the relationship
of APOE-4 and APOE-2 carrier status and clinical phe-
notypes, while adjusting for other relevant variables, a
logistic-regression model was used, with age at onset,
sex, DR2 status, and APOE-2/APOE-4 carrier status as
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Table 2
Probabilities Based on PDT and TRANSMIT (TRM) Analysis of 398 Families of Patients with MS
GLOBAL TEST HAPLOTYPE-SPECIFIC TEST
TRANSMISSIONS TO AFFECTED
OFFSPRING
MARKER(S) df PDTa TRMb
Overtransmitted
Haplotype df TRMb Total No.c
Observed
(%)
Expected
(%)
snp469 1 .51 .22
snp457 1 .86 .80
snp992 1 .38 .71
APOE 2 .99 .70
snp952 1 .59 .72
snp873 1 .41 .07
snp888 1 .53 1.0
snp988 1 .32 .33
873-888 3 … .006 11 1 .06 1,192 6.6 5.8
952-873-888 4 … .01 111 1 .03 1,192 6.3 5.4
873-888-988 4 … .02 112 1 .02 1,192 6.0 5.1
APOE-952-873-888 5 … .005 2111d 1 .02 1,230 4.5 3.8
952-873-888-988 6 … .01 1112 1 .02 1,192 6.1 5.1
APOE-952-873-888-988 6 … .02 21112d 1 .01 1,202 4.5 3.6
NOTE.—Only significant P values (uncorrected for multiple comparisons) are shown for multilocus analyses, for which a
sliding-window approach was used (see “Subjects and Methods” section).
a P value (uncorrected) for sum version of PDT (Martin et al. 2001a); P values for the average version of PDT were similar
(data not shown). Sample comprised 228–284 discordant sib pairs and 371–447 parent-offspring triads.
b P value (uncorrected) for TRANSMIT. Alleles/haplotypes with !3% frequency were combined to ensure that variance of
observed minus expected transmission counts was 5. The robust variance estimator was used throughout. P values were
essentially identical when extended multiplex pedigrees were analyzed and when only a single nuclear family from such pedigrees
was included. Sample comprised 551–615 affected offspring with scorable transmissions.
c Number of transmissions is twice the number of affected offspring.
d The first “2” allele is the APOE-2 allele.
covariates. Patients were classified as having “severe” or
“mild” MS, with “severe” being defined as reaching
EDSS 16 (combined categories 6.5 [need for bilateral
assistance to walk] and 7 [wheelchair dependency])10
years after disease onset (23 patients) and “mild” being
defined as EDSS !3 that continued 110 years after dis-
ease onset (55 patients). The severe MS group included
8 patients with relapsing-remittingMS, 9with secondary
progressive, 3 with primary progressive, and 3 with pro-
gressive-relapsing MS; the mild MS group included 53
patients with relapsing-remitting disease and 2 with sec-
ondary progressive MS. A highly significant association
between age at onset and disease severity was observed
for both severe and mild MS patient groups, as reported
elsewhere (Barcellos et al. 2001). The average age at
onset was 36.8 years (severe), compared with 29.9 years
(nonsevere, ), and 26.5 years (mild), com-Pp .0003
pared with 30.5 years (nonmild, ).Pp .0002
The proportion of APOE-4 carriers was significantly
higher in the severe disease group ( , 39.1%) thannp 9
the nonsevere group ( , 22.7%; odds ratio (OR)np 134
for severe MS p 2.67, 95% confidence interval (CI)
1.12–6.36, ; fig. 2). On the other hand, the pro-Pp .03
portion of APOE-2 carriers was significantly higher in
the mild disease group ( , 25.5%) than in the non-np 14
mild group ( , 16.5%; OR for mild MS p 2.10,np 92
95% CI 1.11–3.95, ; fig. 3). For these analyses,Pp .02
APOE-2 and APOE-4 carriers were compared with
APOE-3/3 individuals. When nonsevere and nonmild
patient groups were restricted to patients with disease
duration 10 years ( with nonsevere MS;np 374
with nonmild MS), very similar results werenp 319
observed ( for association of APOE-4 and severePp .03
disease; for association of APOE-2 and mildPp .01
disease). Exclusion of all primary-progressive patients
from this analysis did not alter our results (data not
shown).
As an extension of the logistic-regression model, a
proportional-odds model (see “Subjects and Methods”
section) with the same covariates was also applied. Here,
three ordered categories of disease severity were used as
the response variable: patients with mild, moderate, or
severe MS; “mild” and “severe” were defined as above,
and all other patients were considered to have “mod-
erate” disease. Results were similar to those from the
logistic-regression model but did not reach statistical sig-
nificance: APOE-2 carriers were more likely to havemild
disease (OR 1.54, 95% CI 0.77–3.08, ), andPp .22
APOE-4 carriers were less likely to have mild disease
(OR 0.79, 95% CI 0.42–1.49, ), when com-Pp .47
pared with APOE-3/3 individuals.
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Table 3
Summary of Clinical/Demographic Characteristics of 614
Patients with MS from 379 Families
Clinical/Demographic
Informationa Mean No. of Years (Range)  SD
Age at onset 30.1 (6–63)  8.8
Disease duration 15.1 (0–59)  10.3
Years to EDSS 7b 15.8 (1–42)  8.3
No. (%) of Patients
Female 457 (74.4)
EDSS:
!3 140 (22.8)
3–!6 209 (34.0)
6 96 (15.6)
6.5 61 (9.9)
7 108 (17.6)
Disease course:
Mild 55 (9.0)
Nonmild 559 (91.0)
Severe 23 (3.8)
Nonsevere 591 (96.2)
Disease type:
Relapsing-remitting 379 (61.7)
Primary progressive 30 (4.9)
Secondary progressive 182 (29.6)
Progressive-relapsing 19 (3.1)
HLA-DR2:
Positive 390 (63.5)
Negative 224 (36.5)
a Disease types and courses are defined in the text.
b A total of 91 patients reached EDSS 7 and had infor-
mation for the corresponding disease duration.
Figure 2 Comparison of APOE genotypes for severe and non-
severe MS. P values from PROC GENMOD, using logistic regression
with correction for familial correlations and adjustment for age at
onset, sex, and DR2 status. Odds ratio of severe MS for APOE-4
carriersp 2.67, 95% CI 1.12–6.36, ; reference group APOE-Pp .03
3/3 genotype.
Survival Analysis
Latency (in years) to EDSS 7 was analyzed as a
censored response variable, using the Cox-regression
model ( patients). The same covariates were in-np 597
cluded, and disease duration was used for patients who
had not reached EDSS7. No significant effect of APOE
genotypes on rate of progression to disability was de-
tected (hazard ratio for APOE-4 carriers p 0.84, 95%
CI 0.51–1.39, ; for APOE-2 carriers p 0.84,Pp .50
95%CI 0.43–1.64, ). The mean latency to EDSSPp .60
7 for APOE-4 carriers was 16.3 years, compared with
15.7 years for noncarriers. Because of the limited num-
ber of individuals with EDSS 7, this patient group
included only 13 and 18 carriers of the APOE-2 and
APOE-4 alleles, respectively.
Discussion
We have used a well-characterized panel of informative
SNPs to analyze the APOE region on chromosome
19q13 for an association with MS. Family-based asso-
ciation analysis identified a disease-associated SNP hap-
lotype, suggesting that an allele in LD with this haplo-
type may confer an increased risk of MS. This result
confirms and extends our previous reports of linkage
and association of the 19q13 region with MS (Pericak-
Vance et al. 2001). From our previous analysis, the effect
of the 19q13 locus is likely to be small, with an estimated
locus-specific that accounts for 4%–6% of thel p 1.5s
overall genetic component in MS (Pericak-Vance et al.
2001). We did not find evidence of an interaction be-
tween the established DR2 effect and the 19q13 loci
examined in this study. Our results also support the pre-
viously suggested hypothesis that APOEmay be involved
in modulation of clinical expression. Specifically, we ob-
served significant associations between APOE-4 and a
more severe form of MS and between APOE-2 and mild
disease. In a survival analysis similar to that employed
by a previous study (Chapman et al. 2001), we failed
to find evidence of faster progression to very severe dis-
ease (EDSS 7) in APOE-4 carriers, possibly because of
a lack of statistical power.
We examined whether the significant haplotype ef-
fect was more likely a result of the presence of a non-
APOE gene that influences MS susceptibility or
whether it could also be explained by the putative
APOE association with disease severity. Using
TRANSMIT output, we analyzed which families con-
tributed positively and negatively, respectively, to the
score for excesstransmission of the 21112 haplotype
(APOE-snp952-snp873-snp888-snp988). If the first
group of families predominantly included patients with
mild MS and the second those with severe MS, this
would suggest that the haplotype effect could be the
result of an association of the APOE-2 allele with mild
MS. However, of the 30 affected offspring whose trans-
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Figure 3 Comparison of APOE genotypes for mild and nonmild
MS. P values from PROC GENMOD, using logistic regression with
correction for familial correlations and adjustment for age at onset,
sex, and DR2 status. Odds ratio of mild MS for APOE-2 carriers p
2.10, 95% CI 1.11–3.95, ; reference group APOE-3/3Pp .02
genotype.
mitted haplotype contributed positively to the TRANS-
MIT score, only 6 had mild MS; and, of the 10 affected
offspring whose transmitted haplotype had a score con-
tribution of 0.5 or less, none had severe MS. This
argues against the hypothesis that the APOE-2 associ-
ation with mild MS found in our patient population
accounts for the haplotype association in the family data
set. Thus, there may be a non-APOE MS susceptibility
locus on 19q13 that is in LD with an SNP haplotype
that includes the APOE-2 allele.
Several studies have reported an association of the
APOE-4 allele and more severe disease, as measured by
older age at onset or by disease activity/progression in-
dex (Dousset et al. 1998; Evangelou et al. 1999; Lucotte
et al. 2000; Fazekas et al. 2001) or by faster rate of
disease progression (Chapman et al. 2001). Fewer stud-
ies have reported APOE effects on MS susceptibility,
although one case-control study reported a higher risk
of developing MS for APOE-4/4 homozygotes (Høgh
et al. 2000). Some biological support for the APOE-4
association with disease progression was suggested by
an MRI study of brain lesions among patients with MS,
which revealed more-extensive tissue destruction or less-
efficient repair in APOE-4 carriers (Fazekas et al. 2000).
However, several studies have not detected any APOE-
4 association with MS (Ferri et al. 1999; Pirttila¨ et al.
2000; Weatherby et al. 2000a, 2000b). In addition to
the obvious influence of sample size, other factors that
may contribute to the lack of consistency across studies
include differences between study populations with re-
spect to proportion of mild and severe MS, proportion
of disease types (relapsing-remitting vs. primary pro-
gressive), or distribution of disease duration. The pres-
ent study confirmed both the strong association of de-
layed disease onset and more severe disease, and the
higher risk of severe MS for APOE-4 carriers. Chapman
et al. (2001) found that the influence of APOE-4 on
disease progression is more pronounced after the first
5 years of disease duration. If APOE genotypes indeed
influence the extent of neuronal repair, it is plausible
that an effect of APOE-4 becomes apparent only in later
disease stages when axonal damage is incurred. This
might explain why we observed an APOE-4 effect only
on the probability of severe disease (defined as pro-
gression to EDSS 16 within the first 10 years of disease)
but no effect on the probability of mild disease.
Fewer studies have examined the association of the
APOE-2 allele and MS phenotypes. One study (Carlin
et al. 2000) suggested that remyelination may be im-
paired in individuals with the APOE-2 allele, since the
apoE-2 isoform was shown to have reduced affinity for
receptors in glial cells. Another study (Ballerini et al.
2000) reported some evidence of a protective effect of
the APOE-2 allele, observing that the time to reach sec-
ondary progression for patients whose initial disease
type was relapsing-remitting was significantly longer for
those with APOE-2/3 genotypes than for those with
APOE-3/3 and 3/4 genotypes. Our results, based on a
substantially larger patient population than those of
most studies published to date, provide additional sup-
port for a protective effect of the APOE-2 allele, in terms
of disease severity. However, it would be useful to refine
the clinical definition of different disease phenotypes be-
yond a binary classification of mild and severe MS, per-
haps on the basis of a combination of neurological ex-
aminations with longitudinal follow-up and MRI scans.
Methodologically, survival analysis may be a more
sensitive instrument for measuring effects on disease
progression, compared with a variable such as pro-
gression index/disease activity score (raw EDSS score
divided by disease duration). A difficulty with this ap-
proach is the determination of which endpoint (EDSS
4, 6, or 7) is clinically most meaningful for assessing
a patient’s disease course. A limitation of our study is
the fact that the only latency variable ascertained so far
is duration to EDSS 7, which is a rather rigorous
definition of severe disease. Such a stringent definition
makes it more difficult to obtain a large enough sample
of patients who experience the event of interest, thus
reducing statistical power to detect small-to-moderate
effects of genotypes on disease progression.
In summary, our results provide further evidence of
a role of APOE in MS progression. It is important to
remember that the statistical associations we found can-
not establish whether APOE itself is the etiologically
relevant polymorphism. As observed elsewhere (Martin
et al. 2000a) for associations of SNPs near APOE with
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risk of late-onset Alzheimer disease, lack of association,
particularly when SNPs in noncoding regions are used,
may not necessarily rule out a candidate gene. On the
other hand, positive association may exist with non-
etiologic polymorphisms that are merely in LD with the
functional allele. Having said this, our haplotype anal-
ysis indicates that APOE itself is unlikely to be the
19q13 susceptibility gene, unless it plays a role in sus-
ceptibility for only a subset of clinically distinct patients
with MS, a role that has yet to be identified. Despite
the positive association of APOE-4 and severe MS, dis-
ease progression may actually be influenced by a dif-
ferent allele that is in LD with APOE-4. For example,
polymorphisms in the APOE promoter region may
play a role in determining disease severity. A previous
study indicated that the AA homozygous state of the
–491 A/T polymorphism in the APOE regulatory region
may be associated with cognitive impairment in patients
with MS (Oliveri et al. 1999). For Alzheimer disease,
several promoter polymorphisms were shown to regu-
late transcriptional activity of the APOE gene and to
correlate with disease risk independently of the APOE-
2 and APOE-4 effects (Artiga et al. 1998; Lambert et
al. 1998). These regulatory region variants, as well as
other candidate genes in 19q13, will be the subject of
future MS studies. Since the potential APOE effect on
MS progression is likely to bemoderate, it will be crucial
to determine the precise clinical phenotype that is most
strongly influenced by this polymorphism. Therefore,
further studies that include detailed clinical measure-
ments of an even larger number of patients and their
families than those provided by this data set are needed
to dissect the role of the 19q13 region in MS.
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